Document:

<PAGE>

                                                                    Exhibit 10.3

                                 PROMISSORY NOTE
                                 ---------------

$200,000                                                         July 24, 2001

     FOR VALUE RECEIVED, CAPSULE COMMUNICATIONS, INC. with principal offices
located at 2 Greenwood Square, 3331 Street Road, Suite 275, Bensalem,
Pennsylvania 19020 hereafter referred to as the "Borrower") promises to pay to
the order of Covist t. Inc. (the "Lender") at its principal office, 150 Clove
Road, Little Falls, New Jersey 07424, the sum of Two Hundred Thousand and 00/100
($200,000) Dollars (the "Principal") with interest thereon as more fully set
forth below.

     This Note shall bear interest from the date hereof and during the term
hereof at a rate of eight and three-quarter (8 3/4) percent per annum. Interest
and Principal shall be payable in full one year from the date above written (the
"Due Date").

     Occurrence of any one of the following events shall be deemed to be a
default under the terms of this Note:

     1.   Failure to pay accrued Interest or the Principal of this Note; or

     2.   Borrower shall make an assignment for the benefit of creditors or
          attempt to effect a composition or arrangement with creditors or be
          adjudged bankrupt or insolvent or any receiver, trustee, liquidator,
          conservator or like officer be appointed to take custody,
          possession or control of any property of Borrower; or Borrower shall
          file any petition, answer of other pleading in any proceeding under
          any Bankruptcy Act as now or hereafter in effect for the purpose of
          affording relief to debtors from their obligations. However, with
          respect to any event of default, as set forth in this subsection 2, no
          default shall be deemed to have occurred unless Borrower fails to
          cure such default within thirty (30) days after the occurrence
          thereof; or

     3.   Upon failure by Borrower to make payment on this Note at its
          stated due date, or if a default (as defined above) shall have
          occurred, the Lender may, addition to such other and further rights
          and remedies provided by law, collect interest from the date of such
          maturity on the principal balance owing hereon at the rate of interest
          of five (5%) percent per annum in excess of that specified in this
          Note, but not in excess of the highest legal rate permitted in the
          State of New Jersey.

     This Note shall also become immediately due and payable in full on not less
than five (5) days prior written notice to Borrower if a certain proposed merger
between Borrower and Lender's subsidiary is not consummated on or prior to
December 31, 2001, or any merger agreement between said parties is terminated
prior to said date, whichever is sooner.

     If this Note is referred to an attorney for collection, regardless of
whether such attorney is an employee of the Lender, Borrower agrees that Lender
shall be entitled to collect reasonable attorney's fees and expenses for the
cost of such collection.
<PAGE>

     This Note may be prepaid in whole or in part without penalty or premium;
however, any prepayment of less than the full principal balance hereof shall be
in the inverse order of maturity.

     This Note shall be payable when due without defense, other than full and
legal payment, offset, deduction or claim of any kind whatsoever.

     The obligations evidenced by this Note are binding upon the Borrower, its
successors and/or assigns.

     Presentment for payment, notice of dishonor, and notice of protest arc
hereby waived by the makers, and any guarantor or and endorser hereof.

     IN WITNESS WHEREOF, the undersigned has caused this Note to be executed as
of the date and year first above written.

ATTEST:                                CAPSULE COMMUNICATIONS, INC.

[SIGNATURE ILLEGIBLE]                      /s/ David Hurwitz
---------------------                  ----------------------------
                                       By: David Hurwitz
                                       Title:   President & CEO

                                       2<PAGE>

                                                                    Exhibit 10.4

                     AMENDMENT NO. 1 TO INVESTMENT AGREEMENT
                     ---------------------------------------

     Reference is made to that certain Investment Agreement (the "Investment
Agreement") dated as of March 20, 2001 by and between Gold & Appel Transfer,
S.A. ("G&A"), located at Omar Hodge Building, Wickhams Cay, Road Town, Tortula,
British Virgin Islands, and Capsule Communications, Inc. ("Capsule"), located at
Ste. 275, 2 Greenwood Square, 3331 Street Road, Bensalem, PA 19020. This
Amendment No. 1 to Investment Agreement (the "Amendment") is made as of July ,
2001 by and between G&A and Capsule.

     Capsule seeks to enter into a merger agreement with Covista Communication,
Inc., a New Jersey corporation. In connection with such proposed merger
agreement, and agreement precaution in order to avoid the applicability of the
New Jersey Shareholders Protection Act, the undersigned hereby agree as follows:

     In consideration of the mutual agreement set forth herein, the receipt and
sufficiency of which are hereby acknowledged, and intending to be legally bound,
and in order to assist Capsule to induce Covista Communications, Inc. to enter
into the proposed merger agreement, the parties hereby agree as follows:

1.   Section 2 of the Investment Agreement is hereby amended to read as follows

          "This loan shall be due and payable on or before August 17, 2001."

2.   Section 3 of the Investment Agreement is hereby deleted in its entirety.

3.   This Amendment may be executed by facsimile and in more than one
counterpart, each one of which shall be deemed an original, and both of which
taken together shall constitute one and the same instrument.

     IN WITNESS WHEREOF, the undersigned have executed this Amendment is of the
date first set forth above.

Capsule Communications, Inc.                       Gold & Appel Transfer, S.A.

By: /s/ David Hurwitz                              By:
  -------------------------------                  -----------------------------
David Hurwitz, President and CEO                   Walt Anderson<PAGE>

                                                                   Exhibit 10.41

                   ADDITIONAL AND ALTERNATIVE TARGET AGREEMENT
                   -------------------------------------------

This Agreement is made and entered into by and between 3-Dimensional
Pharmaceuticals, Inc., a Delaware corporation having its principal place of
business at Eagleview Corporate Center, 665 Stockton Drive, Suite 104, Exton, PA
19341, U.S.A. ("3DP") and Boehringer Ingelheim Pharmaceuticals, Inc., a Delaware
corporation having its principal place of business at 900 Ridgebury Road,
Ridgefield, CT 06877, U.S.A. ("BIPI").

                               W I T N E S S E T H

WHEREAS, 3DP and BIPI entered into an option agreement and an agreement for
collaborative discovery and lead optimization, both as of December 17, 1999
(collectively the "Agreement");

WHEREAS, under the Agreement, BIPI identified an initial Target in the Research
Program against which Qualified Lead Compounds and Active Compounds were to be
developed (capitalized terms used but not defined herein have the same meanings
provided in the Agreement);

WHEREAS, [**]; and

WHEREAS, 3DP and BIPI wish to provide for further work in the Research Program
by adding additional and alternative Targets;

NOW, THEREFORE, in consideration of the mutual covenants and agreements
contained herein and for other good and valuable consideration as set forth
below, the receipt and sufficiency of which is hereby acknowledged, the parties
hereto agree as follows:

1.   The extended term of the Research Program shall be from the execution date
     of this Additional and Alternative Target Agreement and end on March 31,
     2003. (The "First Extension Term") The execution date of this Additional
     and Alternative Target Agreement shall be the date on which both parties
     have signed such agreement. BIPI

**Certain portions of this exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.
<PAGE>

     may further extend the term of the Research Program on an annual basis by
     notifying 3DP in writing at least sixty (60) days prior to the end of the
     First Extension Term or any subsequent one-year extensions then in effect.

2.   BIPI will add [**] Target [**] to the Research Program under the Agreement.
     BIPI shall have the option to change either the [**] or the [**] upon
     thirty (30) days advance written notice to 3DP.

3.   BIPI agrees to pay a nonrefundable, lump sum fee of [**] to 3DP, which fee
     shall be due within thirty (30) days of execution of this Additional and
     Alternative Target Agreement.

4.   BIPI agrees to pay 3DP on a calendar quarterly basis for staff allocated by
     3DP for services to be provided under the Research Program. BIPI agrees to
     pay 3DP for [**] FTEs at a rate of [**] for each calendar quarter, or pro
     rata portion thereof, in which work is continuing on [**] Targets during
     the First Extension Term. For any calendar quarter or portion thereof
     during the First Extension Term in which work is continuing on [**], BIPI
     agrees to pay 3DP for [**] FTEs at a rate of [**]. The quarterly payments
     for the second calendar quarter of 2001 shall be due within thirty (30)
     days of execution of this Additional and Alternative Target Agreement.
     Thereafter, each quarterly payment shall be due in advance on a calendar
     quarterly basis.

5.   Upon at least sixty (60) days advance written notice to 3DP prior to the
     end of any calendar quarter during the First Extension Term, BIPI may
     determine that the Research Program shall continue on [**]. From the first
     day of the next ensuing calendar quarter, each quarterly payment due to 3DP
     by BIPI during the remainder of the First Extension Term, or any subsequent
     one-year extension term then in effect, shall be [**]. Such sum represents
     support for [**] FTEs. A [**] made in accordance with this Paragraph 5
     shall not be considered [**] and no [**] termination fee shall be payable
     with respect to any such [**] under Section 4.3 of the Agreement.

**Certain portions of this exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.
<PAGE>

6.   All draft or proposed press releases and draft or proposed filings to be
     made with the SEC, all as prepared by 3DP, concerning the research Program
     shall be submitted to BIPI as provided in Section 12.10 of the Agreement,
     and shall also be submitted to BIPI, R&D Licensing and Technology Support,
     attn: [**], at the address provided hereinabove for BIPI.

7.   This Additional and Alternative Target Agreement amends the Agreement only
     to the extent set forth above, and in all other respects the Agreement is
     hereby ratified and confirmed.

IN WITNESS WHEREOF, the parties have caused this Additional and Alternative
Target Agreement to be executed in duplicate by their respective duly authorized
officers, each copy of which shall for all purposes be deemed to be an original.

3-DIMENSIONAL                                        BOEHRINGER INGELHEIM
PHARMACEUTICALS, INC.                                PHARMACEUTICALS, INC.

By:      /s/ David C. U'Prichard            By:  /s/ Peter Farina
         -----------------------                 ----------------
Name:    David C.U'Prichard, Ph.D.               Name:  Peter Farina, Ph.D.
Title:   CEO                                     Title: Vice-President Research
Date:    April 19, 2001                          Date:  April 20, 2001

**Certain portions of this exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00028-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00028-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00028-of-00352.parquet"}]]